Eribulin combined with antiangiogenic agents in women with HER2-negative metastatic breast cancer: a retrospective multicenter study.

Mingxia Jiang,Bin Shao,Donggui Wan,Jiaxuan Liu,Maiyue He,Yue Chai,Die Sang,Jiayu Wang,Fei Ma,Ying Fan,Peng Yuan,Binghe Xu,Qiao Li

Therapeutic advances in medical oncology（2023）

引用 0|浏览7

暂无评分

摘要

The results suggest that eribulin combined with antiangiogenic therapy has a meaningful clinical activity and an acceptable safety profile in HER2-negative MBC.

查看译文

关键词

eribulin, antiangiogenic drugs, HER2, MBC, PFS

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要